Back HBV Disease Progression Liver Cancer/HCC

Liver Cancer/HCC

AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study

Nivolumab (Opdivo), an antibody that blocks the PD-1 receptor and restores T-cell anti-tumor activity, appeared safe and was associated with disease control and stabilization in a Phase 1/2 study of patients with hepatocellular carcinoma, according to late-breaking results from the CheckMate 040 study presented at the AASLD Liver Meeting last month in Boston.

alt

Read more:

Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer

A blood test that measures a set of circulating microRNAs (miRNAs) may help identify who will develop hepatitis B virus-related hepatocellular carcinoma (HCC), a type of primary liver cancer, according to research published in the May 24 online edition of OncoTarget.

alt

Read more:

Hepatitis B Vaccine, Hepatitis C Treatment Could Prevent Most Liver Cancer

Widespread vaccination against hepatitis B virus (HBV) and prompt treatment of chronic hepatitis C virus (HCV) -- which together are the most common cause of hepatocellular carcinoma -- could prevent an estimated 80% of liver cancer deaths, according to the World Hepatitis Alliance in an announcement commemorating World Cancer Day.

alt

Read more:

Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C

Overall cancer rates have declined significantly in the U.S. over the past decade thanks to better screening and prevention, with the notable exception of liver cancer, according to a new Annual Report to the Nation on the Status of Cancer. A majority of liver cancer is caused by hepatitis B virus (HBV), which is preventable with a vaccine, or hepatitis C virus (HCV), which can now be cured in most cases.

alt

Read more:

ASCO 2015: PD-1 Checkpoint Inhibitor Nivolumab Shows Promise against Liver Cancer

Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor nivolumab (Opdivo) was a star of the show at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago, with study results showing that the drug demonstrated anti-tumor activity against hepatocellular carcinoma in a Phase 1/2 study, along with further Phase 3 evidence of its effectiveness against lung cancer and melanoma.

alt

Read more: